Zai Lab Limited (HKG:9688)

Market Cap	30.94B
Revenue (ttm)	3.10B
Net Income (ttm)	-2.00B
Shares Out	n/a
EPS (ttm)	-20.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,586,749
Average Volume	7,297,832
Open	27.80
Previous Close	28.50
Day's Range	27.60 - 29.20
52-Week Range	10.56 - 32.50
Beta	1.08
RSI	54.48
Earnings Date	May 8, 2025

About Zai Lab

Zai Lab Limited develops and commercializes products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; VYVGART, a human IgG1 antibody fragment for myesthenia gravis; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; Qinlock to treat gastr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 1,869
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9688

Financial Performance

In 2024, Zai Lab's revenue was $398.99 million, an increase of 49.59% compared to the previous year's $266.72 million. Losses were -$257.10 million, -23.17% less than in 2023.

Financial numbers in USD